Literature DB >> 29965784

Inflammatory Myofibroblastic Tumor in Female Genital Tract.

Pratibha Sharma Shukla1, Khushbakhat Mittal1.   

Abstract

CONTEXT.—: Inflammatory myofibroblastic tumor is a mesenchymal neoplasm of low malignant potential. It was first described in lung, but is known to occur in many extrapulmonary sites including female genital organs, most commonly the uterus. It has a high recurrence rate and a low risk for metastasis. A more recently described aggressive variant, epithelioid myofibroblastic sarcoma with a predilection for the abdominal cavity of males, has also been recently reported to occur in the ovary. This tumor is composed of spindled and epithelioid myofibroblasts in a variably myxoid stroma and commonly shows a fascicular growth pattern with positive staining for desmin, smooth muscle actin, and CD10, which may mimic a smooth muscle or endometrial stromal neoplasm. In the female genital tract it has the potential for being misdiagnosed as a leiomyoma, endometrial stromal tumor, or as a myxoid leiomyosarcoma, resulting in undertreatment or overtreatment. It harbors rearrangements in the ALK gene, resulting in abnormal expression of ALK protein. Immunostaining for ALK is a helpful diagnostic tool. OBJECTIVE.—: To provide a brief review of clinical, histologic, immunohistochemical, and molecular features of inflammatory myofibroblastic tumor with emphasis on possible diagnostic pitfalls in the female genital tract. DATA SOURCES.—: Review of pertinent literature on inflammatory myofibroblastic tumor occurring in the female genital tract and personal experience of the authors. CONCLUSIONS.—: Inflammatory myofibroblastic tumor in the female genital tract can mimic other more common benign and malignant tumors like leiomyoma, leiomyosarcoma, and endometrial stromal sarcoma. Familiarity with clinical and histologic features and use of ALK immunostaining can be critical for correct diagnosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29965784     DOI: 10.5858/arpa.2017-0575-RA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  4 in total

Review 1.  [Endometrial and other rare uterine sarcomas : Diagnostic aspects in the context of the 2020 WHO classification].

Authors:  Doris Mayr; Lars-Christian Horn; Grit Gesine Ruth Hiller; Anne Kathrin Höhn; Elisa Schmoeckel
Journal:  Pathologe       Date:  2022-04-01       Impact factor: 1.011

2.  A unique case of inflammatory myofibroblastic tumor of the liver manifesting with biloma: A case report.

Authors:  Kun Huang; Pingwu Zhao; Jiangying Zhao; Pan Zhao; Jian Yang
Journal:  Oncol Lett       Date:  2022-05-26       Impact factor: 3.111

3.  Clinical characteristics and outcomes of 17 cases of inflammatory myofibroblastic tumor at a University Hospital in China.

Authors:  Wei Song; Yan Zhu
Journal:  Oncol Lett       Date:  2020-11-18       Impact factor: 2.967

4.  Recurrent uterine inflammatory myofibroblastic tumor previously managed as leiomyosarcoma has sustained response to alectinib.

Authors:  Erica V Carballo; Tra V Pham; Gulisa Turashvili; Krisztina Hanley; Kristen D Starbuck; Jane L Meisel
Journal:  Gynecol Oncol Rep       Date:  2022-08-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.